Readily available therapeutic drug monitoring (TDM) of antipsychotic blood levels can provide evidenced-based and personalized psychopharmacologic treatment. Clozapine is the only evidence-based antipsychotic option for treatment resistant schizophrenia and schizophrenia patients with suicidality, with a wealth of data on plasma level response thresholds and the point of futility. For medications such as clozapine, patients and healthcare providers have many situations where TDM is highly relevant in making day-to-day clinical decisions, including differentiating poor adherence with ultrarapid metabolism, and optimizing levels in inadequate responders. During this session, the faculty will discuss the unique place of clozapine for treatment resistant schizophrenia, and the role of TDM in clozapine dosing during titration, and for monitoring ongoing adherence. An open microphone session will follow the presentations.
Course Requirements
To receive ACPE credit for this session, you must:
Sign in (or create a FREE account).
Register for this course.
Review the full content of the activity and reflect upon its teachings.
Your ACPE credit will be submitted directly to CPE Monitor within 48 hours of successful completion of the exam and of the evaluation form if you have provided the relevant information in your profile.
AAPP has invested in supporting the most popular web browsers and leveraging software that our members use daily. Beyond PDF downloads, the rest of the system is built on HTML5, a technology that most up-to-date browsers will support. To access AAPP course materials online, you will need:
A modern web browser with JavaScript and cookies enabled: Chrome is strongly recommended,
or the latest version of Firefox or Safari.
A PDF reader: Chrome built-in, Firefox built-in, Acrobat
or FoxIt
An adequate device and Internet connection:
Processor: Dual-core 2Ghz or higher (Intel i3/i5/i7 or AMD equivalent);
Memory: 4 GB;
Storage: 5 GB available;
Internet speed: 4.0 Mbps (up/down)
AAPP web sites no longer fully support Microsoft Internet Explorer or Windows 8.1 and older. We cannot guarantee that the site will function perfectly on every device and configuration, but using the latest version of the software above will greatly improve your experience.
Faculty Information
Jonathan Meyer, MD Rob Cotes, MD Deanna Kelly, PharmD, BCPP Megan Ehret, PharmD, MS, BCPP
AAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.
Rob Cotes has received research funding (to instituition) from Otsuka, Lunbeck, Roche and Alkermes. He is a consultant to Saladax Biomedical and the American Psychaitric Association.
Deanna Kelly serves as a consultant for Sunovian, Lyndra Therapeutics, and Alkermes. She has received compensation from Saladax Biomedical for presenting at CPNP.
Jonathan Meyer is a consultant to Acadia Pharmaceuticals, Alkermes, Allergan, Intra-Cellular Therapies, and Neurocrine, Noven Pharmaceuticals Inc., Otsuka America Inc., Sunovion Pharamceuticals, and Teva Pharmaceutical Industries. He has received compensation from Saladax Biomedicalfor presenting at CPNP.
Megan Ehret is a Lexi-Comp Consultant/Reviewer. She has received compensation from Saladax Biomedical for presenting at CPNP.
All relevant relationships have been mitigated.
Grant Support
Sponsored by Saladax Biomedical
AAPP websites use cookies to personalize and enhance your experience.
By continuing to use the site, you agree to this collection.
Learn more.
